1. Home
  2. AIRI vs INTS Comparison

AIRI vs INTS Comparison

Compare AIRI & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Industries Group

AIRI

Air Industries Group

HOLD

Current Price

$2.48

Market Cap

12.3M

Sector

Industrials

ML Signal

HOLD

Logo Intensity Therapeutics Inc.

INTS

Intensity Therapeutics Inc.

HOLD

Current Price

$3.13

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AIRI
INTS
Founded
1979
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.3M
13.7M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
AIRI
INTS
Price
$2.48
$3.13
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $19.33
AVG Volume (30 Days)
7.8K
★ 21.0K
Earning Date
11-13-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 24.39
N/A
EPS
★ N/A
N/A
Revenue
★ $47,921,000.00
N/A
Revenue This Year
$4.34
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.30
$0.22
52 Week High
$3.95
$8.06

Technical Indicators

Market Signals
Indicator
AIRI
INTS
Relative Strength Index (RSI) 45.77 36.95
Support Level $2.50 $3.15
Resistance Level $2.75 $4.17
Average True Range (ATR) 0.09 0.34
MACD -0.01 -0.01
Stochastic Oscillator 14.82 10.53

Price Performance

Historical Comparison
AIRI
INTS

About AIRI Air Industries Group

Air Industries Group is an aerospace and defense company. Its manufacturers of precision components and assemblies for large aerospace and defense prime contractors. The company products include landing gears, flight controls, engine mounts and components for aircraft jet engines, ground turbines and other complex machines. The ultimate end-user of products is the U.S. Government, international governments, and commercial global airlines.

About INTS Intensity Therapeutics Inc.

Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.

Share on Social Networks: